Amedeo Smart

Free Medical Literature Service


 

Amedeo

Inflammatory Bowel Diseases

  Free Subscription

Articles published in
Scand J Gastroenterol
    March 2024
  1. KIASAT A, Prast-Nielsen S, Rautiainen S, Engstrand L, et al
    Plasma bile acids in association with Crohn's disease.
    Scand J Gastroenterol. 2024 Mar 20:1-9. doi: 10.1080/00365521.2024.2328592.
    >> Share

  2. RADFORD SJ, Abdul-Aema B, Tench C, Leighton P, et al
    Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service.
    Scand J Gastroenterol. 2024 Mar 19:1-7. doi: 10.1080/00365521.2024.2330588.
    >> Share

  3. MERTZ NIELSEN A, Theede K, Gluud LL, Kiszka-Kanowitz M, et al
    Efficacy of optimised thiopurine therapy in patients with moderate-to-severe ulcerative colitis: retrospective long-term follow-up from two randomised trials.
    Scand J Gastroenterol. 2024 Mar 5:1-5. doi: 10.1080/00365521.2024.2323502.
    >> Share

  4. VIEUJEAN S, Gillard R, Delanaye P, Seidel L, et al
    Matrix gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in crohn's disease.
    Scand J Gastroenterol. 2024;59:296-303.
    >> Share

    February 2024
  5. MIDJORD J, Nielsen KR, Vang AG, Strom M, et al
    Risk of malignancy in a high-incidence population-based cohort of Faroese patients with inflammatory bowel disease from 1960 to 2020 - a Faroese IBD cohort study.
    Scand J Gastroenterol. 2024 Feb 26:1-8. doi: 10.1080/00365521.2024.2320712.
    >> Share

  6. ZEROUGA I, Valeur J, Sommer C, Cvancarova Smastuen M, et al
    Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study.
    Scand J Gastroenterol. 2024 Feb 15:1-9. doi: 10.1080/00365521.2024.2313056.
    >> Share

    January 2024
  7. MALIK S, Loganathan P, Mohan BP
    Letter to editor: effects of vancomycin in primary sclerosing cholangitis with and without inflammatory bowel disease.
    Scand J Gastroenterol. 2024 Jan 30:1-2. doi: 10.1080/00365521.2024.2310168.
    >> Share

  8. THUNBERG J, Granno O, Bergemalm D, Eriksson C, et al
    Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels.
    Scand J Gastroenterol. 2024;59:150-155.
    >> Share

    December 2023
  9. MOLANDER P, Kosunen M, Eronen H, Tillonen J, et al
    Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study.
    Scand J Gastroenterol. 2023 Dec 29:1-8. doi: 10.1080/00365521.2023.2298361.
    >> Share

  10. STRAATMIJER T, van den Akker-van Marle ME, Ponsioen CY, van der Horst D, et al
    Patient preferences in treatment options of ulcerative colitis: a discrete choice experiment.
    Scand J Gastroenterol. 2023 Dec 2:1-8. doi: 10.1080/00365521.2023.2286191.
    >> Share

    November 2023
  11. HARNO-TASIHIN J, Siregar L, Paajanen M, Arkkila P, et al
    Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
    Scand J Gastroenterol. 2023 Nov 25:1-8. doi: 10.1080/00365521.2023.2285229.
    >> Share

  12. ZHANG Y, Jiang W, Xu C, Tian J, et al
    The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease.
    Scand J Gastroenterol. 2023 Nov 22:1-11. doi: 10.1080/00365521.2023.2283387.
    >> Share

  13. ANJIE SI, Hanzel J, Gecse KB, D'Haens GR, et al
    Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
    Scand J Gastroenterol. 2023 Nov 14:1-7. doi: 10.1080/00365521.2023.2278424.
    >> Share

  14. IBORRA M, Ferreiro-Iglesias R, Maria Dolores MA, Mesonero Gismero F, et al
    Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
    Scand J Gastroenterol. 2023 Nov 6:1-9. doi: 10.1080/00365521.2023.2278427.
    >> Share

    October 2023
  15. WANG L, Zhang Y, Wu H, Tang Z, et al
    Intestinal ultrasound score predicts therapeutic outcomes of infliximab in pediatric patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Oct 31:1-8. doi: 10.1080/00365521.2023.2271110.
    >> Share

  16. NURMI E, Rantanen A, Paavilainen E, Haapamaki J, et al
    A quality assessment of inflammatory bowel disease nursing care in Finland: a nationwide cross-sectional descriptive study.
    Scand J Gastroenterol. 2023 Oct 30:1-5. doi: 10.1080/00365521.2023.2276654.
    >> Share

  17. YAN Q, Feng Z, Jiang B, Yao J, et al
    Biological functions of connexins in the development of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Oct 14:1-8. doi: 10.1080/00365521.2023.2267713.
    >> Share

    September 2023
  18. FOSSMARK R, Lirhus SS, Hoivik ML
    The impact of proton pump inhibitors on the course of ulcerative colitis: a cohort study of over 10,000 newly diagnosed patients in Norway.
    Scand J Gastroenterol. 2023 Sep 8:1-6. doi: 10.1080/00365521.2023.2255710.
    >> Share

    August 2023
  19. RANKALA R, Mustonen A, Voutilainen M, Mattila K, et al
    Costs of medications used to treat inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Aug 29:1-5. doi: 10.1080/00365521.2023.2248539.
    >> Share

  20. ZHANG X, Wang P, Yang Y, Gao X, et al
    Monocyte/macrophage mediates the impact of depression on Crohn's disease.
    Scand J Gastroenterol. 2023 Aug 27:1-11. doi: 10.1080/00365521.2023.2245938.
    >> Share

  21. CHEN Y, Sun Z, Li Z, Duan M, et al
    Comparison of endoscopic balloon dilation and surgery for duodenal stricture in patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Aug 25:1-7. doi: 10.1080/00365521.2023.2250495.
    >> Share

  22. CHEN C, Lan B, Xie G, Liu Z, et al
    Analysis and identification of ferroptosis-related genes in ulcerative colitis.
    Scand J Gastroenterol. 2023 Aug 2:1-12. doi: 10.1080/00365521.2023.2240927.
    >> Share

    July 2023
  23. KIM J, Jung JH, Jo H, Kim MH, et al
    Risk of uterine cervical cancer in inflammatory bowel disease: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2023 Jul 30:1-10. doi: 10.1080/00365521.2023.2238101.
    >> Share

  24. BRODERSEN JB, Jensen MD, Juel MA, Kjeldsen J, et al
    Intestinal ultrasound in patients with suspected Crohn's disease - results of a prospective evaluation by trainees.
    Scand J Gastroenterol. 2023 Jul 17:1-7. doi: 10.1080/00365521.2023.2234538.
    >> Share

  25. BARNER-RASMUSSEN N, Sjoblom N, Arola J, Boyd S, et al
    The role of serology, liver function tests and imaging in screening of primary sclerosing cholangitis: the HelPSCreen score.
    Scand J Gastroenterol. 2023 Jul 14:1-8. doi: 10.1080/00365521.2023.2233038.
    >> Share

  26. MARK-CHRISTENSEN A, Jolving LR, Anru PL, Murray JA, et al
    A population-based nationwide study on total colectomy for ulcerative colitis and risk of ten prevalent inflammatory or autoimmune diseases.
    Scand J Gastroenterol. 2023 Jul 6:1-7. doi: 10.1080/00365521.2023.2231586.
    >> Share

  27. KATO I, Minkevitch J, Sun J
    Oncogenic potential of Campylobacter infection in the gastrointestinal tract: narrative review.
    Scand J Gastroenterol. 2023;58:1453-1465.
    >> Share

    June 2023
  28. BANZRAGCH M, Sanli K, Stensvold CR, Kurt O, et al
    Metabarcoding of colonic cleansing fluid reveals unique bacterial members of mucosal microbiota associated with Inflammatory Bowel Disease.
    Scand J Gastroenterol. 2023 Jun 20:1-11. doi: 10.1080/00365521.2023.2223708.
    >> Share

  29. FOLLIN-ARBELET B, Smastuen MC, Hovde O, Jelsness-Jorgensen LP, et al
    Incidence of cancer in patients with ulcerative colitis 30 years after diagnosis (the IBSEN study).
    Scand J Gastroenterol. 2023 Jun 20:1-7. doi: 10.1080/00365521.2023.2223709.
    >> Share

  30. KIASAT A, Rautiainen S, Prast-Nielsen S, Engstrand L, et al
    Evaluation of plasma Short chain fatty acid levels as markers for Inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Jun 5:1-7. doi: 10.1080/00365521.2023.2219357.
    >> Share

    May 2023
  31. BEYSENS S, Wellens J, De Hertogh G, Van Laethem A, et al
    Managing metastatic Crohn's disease: a single center experience, review of the current evidence, and treatment algorithm.
    Scand J Gastroenterol. 2023 May 13:1-9. doi: 10.1080/00365521.2023.2209689.
    >> Share

  32. KIM KW, Koh SJ, Kang HW, Park H, et al
    Atopic dermatitis is associated with the clinical course of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 May 11:1-7. doi: 10.1080/00365521.2023.2209688.
    >> Share

  33. SHI T, Liu W, Li T, Liu H, et al
    HLA-DQ genotype distribution and risk evaluation of celiac disease in Northwest China.
    Scand J Gastroenterol. 2023;58:471-476.
    >> Share

    April 2023
  34. LIU C, Zhan S, Li N, Tu T, et al
    Bile acid alterations associated with indolent course of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Apr 18:1-10. doi: 10.1080/00365521.2023.2200518.
    >> Share

  35. ZHU M, Fan L, Han M, Zhu S, et al
    The usefulness of fecal hemoglobin and calprotectin tests in diagnosing significant bowel diseases: a prospective study.
    Scand J Gastroenterol. 2023;58:368-374.
    >> Share

  36. KRIDIN K, Goral D, Shihade W, Tzur-Bitan D, et al
    Vitiligo and Crohn's disease form an autoimmune cluster: insights from a population-based study.
    Scand J Gastroenterol. 2023;58:354-359.
    >> Share

    March 2023
  37. PAUWELS RWM, Ten Bokkel Huinink S, van der Woude CJ, Doukas M, et al
    Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Mar 27:1-8. doi: 10.1080/00365521.2023.2194009.
    >> Share

  38. LIU Y, Ji X, Huang Y, Li Q, et al
    Older patients benefit more from sequential courses of washed microbiota transplantation than younger population with ulcerative colitis.
    Scand J Gastroenterol. 2023 Mar 2:1-10. doi: 10.1080/00365521.2023.2185476.
    >> Share

    February 2023
  39. PAN Y, Huang X, Zhou Z, Yang X, et al
    Clinical significance of a novel uric-acid-based biomarker in the prediction of disease activity and response to infliximab therapy in Crohn's disease.
    Scand J Gastroenterol. 2023 Feb 24:1-7. doi: 10.1080/00365521.2023.2175181.
    >> Share

  40. WANG L, Xu C, Zhang Y, Jiang W, et al
    External validation and comparison of simple ultrasound activity score and international bowel ultrasound segmental activity score for Crohn's disease.
    Scand J Gastroenterol. 2023 Feb 23:1-7. doi: 10.1080/00365521.2023.2181038.
    >> Share

  41. JENSEN KJ, Jensen CB, Wennerstrom C, Burisch J, et al
    Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Scand J Gastroenterol. 2023 Feb 21:1-11. doi: 10.1080/00365521.2023.2173988.
    >> Share

  42. WIKEN TH, Hoivik ML, Buer L, Warren DJ, et al
    Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.
    Scand J Gastroenterol. 2023 Feb 17:1-11. doi: 10.1080/00365521.2023.2176252.
    >> Share

  43. JORGENSEN KK, Hoivik ML, Chopra A, Benth JS, et al
    Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
    Scand J Gastroenterol. 2023 Feb 14:1-9. doi: 10.1080/00365521.2023.2177884.
    >> Share

  44. LINDH S, Bengtsson J, Kaczynski J
    Is biologic therapy effective for antibiotic-refractory pouchitis?
    Scand J Gastroenterol. 2023;58:148-150.
    >> Share

    December 2022
  45. ARMS-WILLIAMS B, Hawthorne AB, Cannings-John R, Berry A, et al
    Changes in incidence and clinical features of inflammatory bowel disease in Cardiff, UK over 50 years: an update for 2005-2016.
    Scand J Gastroenterol. 2022 Dec 23:1-8. doi: 10.1080/00365521.2022.2158754.
    >> Share

  46. DANDOY P, Louis E, Gast P, Poncin M, et al
    Factors associated with the efficacy and safety of endoscopic dilatation of symptomatic strictures in Crohn's disease: a retrospective cohort study.
    Scand J Gastroenterol. 2022 Dec 19:1-9. doi: 10.1080/00365521.2022.2156808.
    >> Share

  47. RUEDA GARCIA JL, Suarez Ferrer C, Martin-Arranz E, Garcia-Ramirez L, et al
    Randomized clinical trial evaluating three low-volume preparations for colonoscopy in outpatients with Inflammatory Bowel Disease: the EII-PREP trial.
    Scand J Gastroenterol. 2022 Dec 15:1-8. doi: 10.1080/00365521.2022.2153618.
    >> Share

  48. CARON B, Laurent V, Odille F, Danese S, et al
    New magnetic resonance imaging sequences for fibrosis assessment in Crohn's disease: a pilot study.
    Scand J Gastroenterol. 2022;57:1450-1453.
    >> Share

  49. GAWEL K, Dabkowski K, Zawada I, Starzynska T, et al
    Progression risk factors of ulcerative proctitis.
    Scand J Gastroenterol. 2022;57:1406-1411.
    >> Share

    November 2022
  50. ERONEN H, Oksanen P, Jussila A, Huhtala H, et al
    Long-term outcomes of patients with acute severe ulcerative colitis treated with cyclosporine rescue therapy.
    Scand J Gastroenterol. 2022 Nov 17:1-6. doi: 10.1080/00365521.2022.2143727.
    >> Share

  51. KRARUP AL, Larsen L, Nayeb AB, Grontved S, et al
    Less prevalent use of biologics for inflammatory bowel disease in patients from Non-Academic hospitals - a Danish register-based study of a region with 580,000 citizens.
    Scand J Gastroenterol. 2022 Nov 10:1-6. doi: 10.1080/00365521.2022.2143726.
    >> Share

  52. GOETGEBUER RL, van der Woude CJ, Bakker L, van der Eijk AA, et al
    The diagnosis and management of CMV colitis in IBD patients shows high practice variation: a national survey among gastroenterologists.
    Scand J Gastroenterol. 2022;57:1321-1326.
    >> Share

  53. YU L, Zhang MM, Hou JG
    Molecular and cellular pathways in colorectal cancer: apoptosis, autophagy and inflammation as key players.
    Scand J Gastroenterol. 2022;57:1279-1290.
    >> Share

  54. BLESL A, Petritsch W, Binder L, Furst S, et al
    Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Scand J Gastroenterol. 2022;57:1327-1330.
    >> Share

  55. BRUNET-HOUDARD S, Monmousseau F, Berthon G, Des Garets V, et al
    How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients.
    Scand J Gastroenterol. 2022;57:1312-1320.
    >> Share

  56. LEE CH, Huang S, Hsu P, Leong RW, et al
    Low-dose IL-2 may enhance the effect of vedolizumab.
    Scand J Gastroenterol. 2022;57:1404-1405.
    >> Share

    October 2022
  57. SHIGA H, Takahashi T, Shiraki M, Kojima Y, et al
    Reduced antiviral seropositivity among patients with inflammatory bowel disease treated with immunosuppressive agents.
    Scand J Gastroenterol. 2022 Oct 12:1-8. doi: 10.1080/00365521.2022.2132831.
    >> Share

  58. NISHIO M, Hirasawa K, Chiba S, Ozeki Y, et al
    Endoscopic resection is feasible for high-grade dysplasia in patients with ulcerative colitis.
    Scand J Gastroenterol. 2022 Oct 6:1-6. doi: 10.1080/00365521.2022.2107878.
    >> Share

    September 2022
  59. MANGIA M, Giuffrida E, Figini V, Colombo A, et al
    Agreement between patients and physicians on scores of inflammatory bowel disease activity and burden assessed on a telemonitoring platform.
    Scand J Gastroenterol. 2022 Sep 23:1-8. doi: 10.1080/00365521.2022.2124538.
    >> Share

  60. GROS B, Soto P, Causse M, Marin S, et al
    Impact of Clostridioides difficile infection in patients admitted with ulcerative colitis.
    Scand J Gastroenterol. 2022 Sep 8:1-8. doi: 10.1080/00365521.2022.2121175.
    >> Share

    August 2022
  61. BJORLYKKE KH, Jahnsen J, Brynskov J, Molander P, et al
    Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia.
    Scand J Gastroenterol. 2022 Aug 23:1-9. doi: 10.1080/00365521.2022.2108684.
    >> Share

  62. BOAZ E, Bar-Gil Shitrit A, Schechter M, Goldin E, et al
    Inflammatory bowel disease in families with four or more affected first-degree relatives.
    Scand J Gastroenterol. 2022 Aug 5:1-5. doi: 10.1080/00365521.2022.2106153.
    >> Share

  63. SAJJADI S, Svensson Neufert R, Ruhr E, Tryggmo S, et al
    Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients: comparison of retrospective cohorts.
    Scand J Gastroenterol. 2022 Aug 2:1-5. doi: 10.1080/00365521.2022.2106151.
    >> Share

  64. LERANG F, Holst R, Henriksen M, Wahlberg H, et al
    Antitumour necrosis factor alpha treatment in Crohn's disease: long-term efficacy, side effects and need for surgery.
    Scand J Gastroenterol. 2022;57:921-929.
    >> Share

    July 2022
  65. WONG ECL, Hasan B, Dulai PS, Marshall JK, et al
    End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis.
    Scand J Gastroenterol. 2022 Jul 30:1-8. doi: 10.1080/00365521.2022.2105169.
    >> Share

  66. HELLSTROM PM, Gemmen E, Ward HA, Koo H, et al
    Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study.
    Scand J Gastroenterol. 2022 Jul 14:1-8. doi: 10.1080/00365521.2022.2090275.
    >> Share

  67. MEYER A, Fumery M, Peyrin-Biroulet L, Filippi J, et al
    Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
    Scand J Gastroenterol. 2022 Jul 12:1-9. doi: 10.1080/00365521.2022.2095668.
    >> Share

  68. BOKS M, Lilja M, Widerstrom M, Karling P, et al
    Increased incidence of late-onset inflammatory bowel disease and microscopic colitis after a Cryptosporidium hominis outbreak.
    Scand J Gastroenterol. 2022 Jul 8:1-7. doi: 10.1080/00365521.2022.2094722.
    >> Share

  69. LUKAS M, Kolar M, Reissigova J, Duricova D, et al
    A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
    Scand J Gastroenterol. 2022;57:814-824.
    >> Share

    June 2022
  70. KOUKI M, Caron B, Malgras A, Ayav A, et al
    Weight change after colectomy for ulcerative colitis.
    Scand J Gastroenterol. 2022 Jun 20:1-3. doi: 10.1080/00365521.2022.2089537.
    >> Share

  71. BAUER N, Kairey L, Schlee C, Uecker C, et al
    Use of complementary and alternative medicine (CAM) in patients with inflammatory bowel disease (IBD): results from a German nationwide survey of 2019 compared to a previous survey of 2002.
    Scand J Gastroenterol. 2022 Jun 18:1-7. doi: 10.1080/00365521.2022.2078667.
    >> Share

  72. PUOLANNE AM, Qadri S, Vesterinen T, Hiltunen S, et al
    Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin?
    Scand J Gastroenterol. 2022 Jun 13:1-8. doi: 10.1080/00365521.2022.2084345.
    >> Share

    May 2022
  73. FERNANDES SR, Rodrigues IC, Serrazina J, Botto IA, et al
    Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease.
    Scand J Gastroenterol. 2022 May 22:1-7. doi: 10.1080/00365521.2022.2076567.
    >> Share

  74. MONMOUSSEAU F, Mulot L, Rusch E, Picon L, et al
    Predictors of each quality of life dimension in Crohn's disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics.
    Scand J Gastroenterol. 2022;57:566-573.
    >> Share

    April 2022
  75. CHRISTENSEN KR, Ainsworth MA, Steenholdt C, Buhl S, et al
    Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics.
    Scand J Gastroenterol. 2022 Apr 12:1-7. doi: 10.1080/00365521.2022.2060049.
    >> Share

  76. VOLKERS A, Bossuyt P, de Jong J, Pouillon L, et al
    Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study.
    Scand J Gastroenterol. 2022;57:439-445.
    >> Share

  77. KIM JE, Won H, Kim YH, Kim ER, et al
    Specificity of clinical decision support tools for vedolizumab and ustekinumab in biologically naive patients with Crohn's disease.
    Scand J Gastroenterol. 2022;57:446-448.
    >> Share

  78. HIRSCH RD, Keung C, Con D, Vasudevan A, et al
    Direct health care costs of managing perianal Crohn's Disease in a population based cohort.
    Scand J Gastroenterol. 2022;57:432-438.
    >> Share

  79. YLISAUKKO-OJA T, Puttonen M, Jokelainen J, Koivusalo M, et al
    Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.
    Scand J Gastroenterol. 2022;57:415-423.
    >> Share

  80. BRODERSEN JB, Andersen KW, Jensen MD
    Adherence to the bowel cleansing regimen for pan-enteric capsule endoscopy in patients with suspected Crohn's disease and factors affecting the image quality.
    Scand J Gastroenterol. 2022;57:501-506.
    >> Share

  81. HERMANSON M, Bengtson J, Croix H, Lindholm E, et al
    Ileal pouch-anal anastomosis; 18 years of experience and outcomes across two generations of surgeons at a tertiary center in Sweden.
    Scand J Gastroenterol. 2022;57:401-405.
    >> Share

    March 2022
  82. REPO M, Pessi J, Wirtanen E, Hiltunen P, et al
    Frequency and clinical significance of histologic upper gastrointestinal tract findings in children with inflammatory bowel disease.
    Scand J Gastroenterol. 2022 Mar 31:1-5. doi: 10.1080/00365521.2022.2057197.
    >> Share

  83. GAO X, Huang D, Yang LS, He AQ, et al
    Identification of gut microbiome and transcriptome changes in ulcerative colitis and pouchitis.
    Scand J Gastroenterol. 2022 Mar 11:1-11. doi: 10.1080/00365521.2022.2047221.
    >> Share

  84. ERONEN H, Kolehmainen S, Koffert J, Koskinen I, et al
    Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study.
    Scand J Gastroenterol. 2022 Mar 3:1-6. doi: 10.1080/00365521.2022.2045350.
    >> Share

    February 2022
  85. MATTILA K, Rankala R, Voutilainen M, Mustonen A, et al
    Inflammatory bowel disease: perceived impact on leisure-time activities.
    Scand J Gastroenterol. 2022 Feb 23:1-6. doi: 10.1080/00365521.2022.2042593.
    >> Share

  86. APPEL CW, Pedersen SC, Nielsen AS, Larsen BF, et al
    Telemedicine based on patient-reported outcomes in management of patients with inflammatory bowel disease in a real-life setting - a before and after cohort study.
    Scand J Gastroenterol. 2022 Feb 23:1-7. doi: 10.1080/00365521.2022.2041083.
    >> Share

  87. KHERA AJ, Chase JW, Stillman BC, Salzberg M, et al
    Pelvic floor behavioral treatment for fecal incontinence and constipation in quiescent inflammatory bowel disease.
    Scand J Gastroenterol. 2022 Feb 21:1-7. doi: 10.1080/00365521.2022.2039280.
    >> Share

  88. WICKRAMASEKERA N, Coates E, Barr A, Lee MJ, et al
    Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment.
    Scand J Gastroenterol. 2022 Feb 10:1-10. doi: 10.1080/00365521.2022.2036808.
    >> Share

  89. HILON J, Alstad T, Hasseus B, Kashani H, et al
    Phenotype of Crohn's disease according to the Montreal classification in relation to dental health status.
    Scand J Gastroenterol. 2022;57:183-189.
    >> Share

  90. O'GRADY J, Carey BW, Kavanagh RG, O'Connell A, et al
    Making computed tomography safer for patients with Crohn's disease.
    Scand J Gastroenterol. 2022;57:175-182.
    >> Share

  91. ZHULINA Y, Udumyan R, Tysk C, Halfvarson J, et al
    Mortality in patients with Crohn's disease in Orebro, Sweden 1963-2010.
    Scand J Gastroenterol. 2022;57:158-164.
    >> Share

    January 2022
  92. JELSNESS-JORGENSEN LP, Moum B, Grimstad T, Jahnsen J, et al
    The multidimensional fatigue inventory (MFI-20): psychometrical testing in a Norwegian sample of inflammatory bowel disease (IBD) patients.
    Scand J Gastroenterol. 2022 Jan 25:1-7. doi: 10.1080/00365521.2022.2029939.
    >> Share

  93. GE C, Lu Y, Shen H, Zhu L, et al
    Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis.
    Scand J Gastroenterol. 2022 Jan 7:1-12. doi: 10.1080/00365521.2021.2022193.
    >> Share

    December 2021
  94. WARD D, Neumann A, Hendel JW, Riis LB, et al
    Danish Society for Gastroenterology and Hepatology's clinical recommendations for colonoscopic surveillance for colorectal dysplasia and cancer in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2021 Dec 30:1-8. doi: 10.1080/00365521.2021.2022191.
    >> Share

  95. DIGNASS AU, Paridaens K, Al Awadhi S, Begun J, et al
    Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis.
    Scand J Gastroenterol. 2021 Dec 21:1-8. doi: 10.1080/00365521.2021.2015801.
    >> Share

  96. WYNNE J, Kozuch P
    Medical marijuana for inflammatory bowel disease: the highs and lows.
    Scand J Gastroenterol. 2021 Dec 17:1-9. doi: 10.1080/00365521.2021.1998604.
    >> Share

  97. EL-DALLAL M, Saroufim A, Systrom H, Ballou S, et al
    Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study.
    Scand J Gastroenterol. 2021 Dec 11:1-9. doi: 10.1080/00365521.2021.2013527.
    >> Share

  98. ZHANG M, Bai X, Zhang H, You Y, et al
    The role of cytomegalovirus colitis on short- and long-term outcomes for patients with ulcerative colitis.
    Scand J Gastroenterol. 2021 Dec 11:1-8. doi: 10.1080/00365521.2021.2006298.
    >> Share

  99. WALTER S, Jones MP, Sjodahl J, Stjernman H, et al
    Measuring the impact of gastrointestinal inconvenience and symptoms on perceived health in the general population - validation of the Short Health Scale for gastrointestinal symptoms (SHS-GI).
    Scand J Gastroenterol. 2021;56:1406-1413.
    >> Share

  100. LUNDQUIST LR, Rasmussen B, Waldorff FB, Wehberg S, et al
    Predictors of health-related quality of life in patients with Crohn's disease receiving biological therapy.
    Scand J Gastroenterol. 2021;56:1434-1441.
    >> Share

  101. WEI Y, Chen T, Yang W, Li H, et al
    Detection of a novel antigen for Crohn's disease.
    Scand J Gastroenterol. 2021;56:1427-1433.
    >> Share

  102. HAN ZM, Chen BX, Zhou Q, Liu HB, et al
    Predictors of infliximab-induced deep remission in treatment-naive patients with isolated small bowel Crohn's disease.
    Scand J Gastroenterol. 2021;56:1422-1426.
    >> Share

    November 2021
  103. GRIMSTAD T, Skjellerudsveen BM, Kvaloy JT, Skoie IM, et al
    The influence of disease activity on fatigue in patients with ulcerative colitis - a longitudinal study.
    Scand J Gastroenterol. 2021 Nov 30:1-8. doi: 10.1080/00365521.2021.2007281.
    >> Share

  104. CHRISTENSEN KR, Steenholdt C, Buhl S, Brynskov J, et al
    A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence.
    Scand J Gastroenterol. 2021 Nov 13:1-8. doi: 10.1080/00365521.2021.2002397.
    >> Share

  105. FURUYA Y, Fukai K, Nakazawa S, Kojimahara N, et al
    Occupational physical activity differentially affects the risk for developing later-onset Crohn's disease and ulcerative colitis among middle-aged and older populations.
    Scand J Gastroenterol. 2021 Nov 11:1-8. doi: 10.1080/00365521.2021.1999495.
    >> Share

  106. TSUJII Y, Nishida T, Osugi N, Fujii Y, et al
    Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5-aminosalicylate acid: a single-center, observational study.
    Scand J Gastroenterol. 2021 Nov 9:1-7. doi: 10.1080/00365521.2021.1998601.
    >> Share

  107. JORISSEN C, Verstockt B, Schils N, Sabino J, et al
    Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients.
    Scand J Gastroenterol. 2021;56:1323-1327.
    >> Share

  108. WANG S, Zhang YR, Yu YB
    The important role of fungi in inflammatory bowel diseases.
    Scand J Gastroenterol. 2021;56:1312-1322.
    >> Share

    October 2021
  109. LINDHAGEN S, Karling P
    A more frequent disease monitorering but no increased disease activity in patients with inflammatory bowel disease during the first year of the SARS-CoV-2 pandemic. A retrospective study.
    Scand J Gastroenterol. 2021 Oct 26:1-6. doi: 10.1080/00365521.2021.1993328.
    >> Share

  110. SHIMODAIRA Y, Watanabe K, Fukuda S, Watanabe N, et al
    Limited endoscopic mucosal inflammation on equivalent to Mayo endoscopic subscore of 0 unaffect clinical relapse of ulcerative colitis.
    Scand J Gastroenterol. 2021 Oct 18:1-4. doi: 10.1080/00365521.2021.1991467.
    >> Share

  111. ALIPOUR O, Lee V, Tejura TK, Wilson ML, et al
    The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD.
    Scand J Gastroenterol. 2021;56:1175-1181.
    >> Share

  112. PRIMAS C, Hopf G, Reinisch S, Baumann L, et al
    Role of fecal calprotection in predicting endoscopic recurrence in postoperative Crohn's disease.
    Scand J Gastroenterol. 2021;56:1169-1174.
    >> Share

    September 2021
  113. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Long-term maintenance treatment with 300 mg thiamine for fatigue in patients with inflammatory bowel disease: results from an open-label extension of the TARIF study.
    Scand J Gastroenterol. 2021 Sep 30:1-7. doi: 10.1080/00365521.2021.1983640.
    >> Share

  114. LEHTOMAKI J, Nikkonen A, Merras-Salmio L, Hiltunen P, et al
    Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2021 Sep 21:1-6. doi: 10.1080/00365521.2021.1977843.
    >> Share

  115. ATTAUABI M, Hoglund C, Fassov J, Pedersen KB, et al
    Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.
    Scand J Gastroenterol. 2021;56:1040-1048.
    >> Share

  116. LI Y, Pan J, Zhou N, Fu D, et al
    A random forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters.
    Scand J Gastroenterol. 2021;56:1030-1039.
    >> Share

    August 2021
  117. VAN ERP LW, Groenen MJM, Heida W, Wisse J, et al
    Mobile application to monitor inflammatory bowel disease patients on intravenous biologic treatment: a feasibility study.
    Scand J Gastroenterol. 2021 Aug 27:1-8. doi: 10.1080/00365521.2021.1966832.
    >> Share

  118. LING F, Tu L, Li J, Chen Y, et al
    Psychological aspect of patients with inflammatory bowel disease, which may be related to the quality of life, sleep and disease characteristics.
    Scand J Gastroenterol. 2021 Aug 27:1-9. doi: 10.1080/00365521.2021.1966093.
    >> Share

  119. ERIKSSON C, Visuri I, Vigren L, Nilsson L, et al
    Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.
    Scand J Gastroenterol. 2021 Aug 20:1-8. doi: 10.1080/00365521.2021.1963466.
    >> Share

  120. FART F, Salihovic S, McGlinchey A, Gareau MG, et al
    Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects ex vivo in murine intestinal tissue.
    Scand J Gastroenterol. 2021 Aug 12:1-10. doi: 10.1080/00365521.2021.1961306.
    >> Share

  121. KIM HM, Kim JH, Lee JK, Kang DR, et al
    Age- and sex-specific risk of colorectal cancer in incident ulcerative colitis during the first 10 years after diagnosis: a nationwide population-based study.
    Scand J Gastroenterol. 2021 Aug 10:1-7. doi: 10.1080/00365521.2021.1958370.
    >> Share

  122. LUDVIGSSON JF, Holmgren J, Grip O, Halfvarson J, et al
    Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population: a nationwide register-based cohort study 2002-2017.
    Scand J Gastroenterol. 2021 Aug 8:1-11. doi: 10.1080/00365521.2021.1924259.
    >> Share

  123. RONNBLOM A, Ljunggren O, Karlbom U
    Complications and adverse effects related to surgical and medical treatment in patients with inflammatory bowel disease in a prospectively recruited population-based cohort.
    Scand J Gastroenterol. 2021 Aug 8:1-8. doi: 10.1080/00365521.2021.1961309.
    >> Share

    July 2021
  124. ANISDAHL K, Svatun Lirhus S, Medhus AW, Moum B, et al
    First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.
    Scand J Gastroenterol. 2021 Jul 28:1-6. doi: 10.1080/00365521.2021.1955147.
    >> Share

  125. ATIA O, Gupta A, Travis S, Turner D, et al
    The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis.
    Scand J Gastroenterol. 2021 Jul 14:1-7. doi: 10.1080/00365521.2021.1947368.
    >> Share

  126. CHEN BX, Han ZM, Zhou Q, Liu HB, et al
    Efficacy of infliximab in treatment-naive patients with stricturing small bowel Crohn's disease.
    Scand J Gastroenterol. 2021;56:812-819.
    >> Share

    June 2021
  127. KOLEHMAINEN S, Ylisaukko-Oja T, Jokelainen J, Koivusalo M, et al
    Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
    Scand J Gastroenterol. 2021 Jun 21:1-8. doi: 10.1080/00365521.2021.1938206.
    >> Share

  128. KRISTENSEN VA, Opheim R, Perminow G, Huppertz-Hauss G, et al
    Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway.
    Scand J Gastroenterol. 2021 Jun 21:1-7. doi: 10.1080/00365521.2021.1922746.
    >> Share

  129. SIPPONEN T, Af Bjorkesten CG, Hallinen T, Ilus T, et al
    A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in Finland.
    Scand J Gastroenterol. 2021;56:661-670.
    >> Share

  130. FORSS A, Clements M, Myrelid P, Strid H, et al
    Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
    Scand J Gastroenterol. 2021;56:680-686.
    >> Share

  131. ROOSENBOOM B, Horjus Talabur Horje CS, Smids C, Leeuwis JW, et al
    Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies.
    Scand J Gastroenterol. 2021;56:671-679.
    >> Share

    May 2021
  132. LOPEZ-SERRANO A, Suarez MJ, Beso P, Algarra A, et al
    Virtual chromoendoscopy with iSCAN as an alternative method to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammatory bowel disease: a case-control study.
    Scand J Gastroenterol. 2021 May 27:1-9. doi: 10.1080/00365521.2021.1925339.
    >> Share

  133. SIGURDSSON GV, Schmidt S, Mellstrom D, Ohlsson C, et al
    Physical exercise is associated with beneficial bone mineral density and body composition in young adults with childhood-onset inflammatory bowel disease.
    Scand J Gastroenterol. 2021 May 4:1-9. doi: 10.1080/00365521.2021.1913759.
    >> Share

    April 2021
  134. RUBIN DE CELIX C, Chaparro M, Moreno JA, Santander C, et al
    Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience.
    Scand J Gastroenterol. 2021 Apr 27:1-6. doi: 10.1080/00365521.2021.1918758.
    >> Share

  135. VAN DER GIESSEN J, Fuhler GM, van der Woude CJ
    A first pregnancy seems associated with a positive effect on the course of inflammatory bowel disease: data from a prospective pregnancy cohort.
    Scand J Gastroenterol. 2021 Apr 20:1-6. doi: 10.1080/00365521.2021.1910996.
    >> Share

  136. RANKALA R, Mattila K, Voutilainen M, Mustonen A, et al
    Inflammatory bowel disease-related economic costs due to presenteeism and absenteeism.
    Scand J Gastroenterol. 2021 Apr 7:1-6. doi: 10.1080/00365521.2021.1908416.
    >> Share

  137. BROMS G, Soderling J, Sachs MC, Halfvarson J, et al
    Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register - a validation study.
    Scand J Gastroenterol. 2021;56:410-421.
    >> Share

  138. SINGH H, Nguyen T, Pho C, Giles E, et al
    Early Infliximab in Crohn's is associated with decreased intestinal surgery and similar health care costs.
    Scand J Gastroenterol. 2021;56:397-402.
    >> Share

    March 2021
  139. MOUM KM, Moum B, Opheim R
    Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.
    Scand J Gastroenterol. 2021 Mar 26:1-7. doi: 10.1080/00365521.2021.1901308.
    >> Share

  140. BEKIC D, Belosic Halle Z
    Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.
    Scand J Gastroenterol. 2021 Mar 25:1-5. doi: 10.1080/00365521.2021.1902561.
    >> Share

  141. QVIST N, Vadstrup K, Alulis S, Borsi A, et al
    Increased use of biologics in the era of TNF-alpha inhibitors did not reduce surgical rate but prolonged the time from diagnosis to first time intestinal resection among patients with Crohn's disease and ulcerative colitis - a Danish register-based st
    Scand J Gastroenterol. 2021 Mar 18:1-8. doi: 10.1080/00365521.2021.1897670.
    >> Share

  142. BONNAUD G, Haennig A, Altwegg R, Caron B, et al
    Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI((R)) on quality of life and quality of care in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2021 Mar 10:1-7. doi: 10.1080/00365521.2021.1894602.
    >> Share

  143. ARBOGAST JP, Urbanik S, Schmidt R, Mennigen R, et al
    Impact of the Crohn's disease digestive damage score (Lemann Index) on the perioperative course in patients with Crohn's disease and ileocolic anastomosis.
    Scand J Gastroenterol. 2021;56:239-246.
    >> Share

    February 2021
  144. ANKERSEN DV, Weimers P, Marker D, Teglgaard Peters-Lehm C, et al
    Costs of electronic health vs. standard care management of inflammatory bowel disease across three years of follow-up-a Danish register-based study.
    Scand J Gastroenterol. 2021 Feb 28:1-10. doi: 10.1080/00365521.2021.1892176.
    >> Share

  145. RONNBLOM A, Karlbom U
    Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort.
    Scand J Gastroenterol. 2021 Feb 12:1-7. doi: 10.1080/00365521.2021.1882553.
    >> Share

    January 2021
  146. ERONEN H, Ilus T, Jussila A, Huhtala H, et al
    Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids.
    Scand J Gastroenterol. 2021 Jan 26:1-8. doi: 10.1080/00365521.2020.1867892.
    >> Share

  147. ATTAUABI M, Burisch J, Seidelin JB
    Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature.
    Scand J Gastroenterol. 2021;56:53-58.
    >> Share

  148. YANG Y, Cui X, Li J, Wang H, et al
    Clinical evaluation of vitamin D status and its relationship with disease activity and changes of intestinal immune function in patients with Crohn's disease in the Chinese population.
    Scand J Gastroenterol. 2021;56:20-29.
    >> Share

    December 2020
  149. DORE MP, Fanciulli G, Manca A, Cocco V, et al
    Clinically relevant thyroid disorders and inflammatory bowel disease are inversely related: a retrospective case-control study.
    Scand J Gastroenterol. 2020 Dec 16:1-6. doi: 10.1080/00365521.2020.1861323.
    >> Share

  150. XI W, Li Z, Ren R, Sai XY, et al
    Effect of antibiotic therapy in patients with ulcerative colitis: a meta-analysis of randomized controlled trials.
    Scand J Gastroenterol. 2020 Dec 12:1-9. doi: 10.1080/00365521.2020.1858958.
    >> Share

  151. DE JONG ME, Taal E, Thomas PWA, Romkens TEH, et al
    Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Dec 10:1-7. doi: 10.1080/00365521.2020.1857430.
    >> Share

  152. STRIK AS, Lowenberg M, Mould DR, Berends SE, et al
    Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial.
    Scand J Gastroenterol. 2020 Dec 8:1-10. doi: 10.1080/00365521.2020.1856405.
    >> Share

  153. OSTLUND I, Werner M, Karling P
    Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Dec 7:1-8. doi: 10.1080/00365521.2020.1854342.
    >> Share

  154. KRISTJANSSON VB, Lund SH, Grondal G, Sveinsdottir SV, et al
    Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018.
    Scand J Gastroenterol. 2020 Dec 5:1-7. doi: 10.1080/00365521.2020.1854847.
    >> Share

    November 2020
  155. LAMERS CR, de Roos NM, Bongers CCWG, Ten Haaf DSM, et al
    Repeated prolonged moderate-intensity walking exercise does not appear to have harmful effects on inflammatory markers in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Nov 19:1-8. doi: 10.1080/00365521.2020.1845791.
    >> Share

  156. KRISHNAPRASAD K, Walsh A, Begun J, Bell S, et al
    Crohn's Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Nov 8:1-8. doi: 10.1080/00365521.2020.1839960.
    >> Share

  157. WALENTYNOWICZ M, Van de Pavert I, Coenen S, Fierens L, et al
    Worries and concerns of inflammatory bowel disease (IBD) patients in Belgium - a validation of the Dutch rating form.
    Scand J Gastroenterol. 2020 Nov 1:1-6. doi: 10.1080/00365521.2020.1839962.
    >> Share

    October 2020
  158. ANKERSEN DV, Weimers P, Marker D, Johannesen T, et al
    eHealth: Disease activity measures are related to the faecal gut microbiota in adult patients with ulcerative colitis.
    Scand J Gastroenterol. 2020 Oct 12:1-10. doi: 10.1080/00365521.2020.1829031.
    >> Share

    April 2020
  159. ZHANG CC, Voitl R, Hippchen T, Weiss KH, et al
    Evaluation of two functional CD24 polymorphisms in primary sclerosing cholangitis.
    Scand J Gastroenterol. 2020 Apr 24:1-7. doi: 10.1080/00365521.2020.1755357.
    >> Share

  160. VON VOLKMANN HL, Bronstad I, Tronstad RR, Dizdar V, et al
    Plasma levels of guanylins are reduced in patients with Crohn's disease.
    Scand J Gastroenterol. 2020 Apr 20:1-5. doi: 10.1080/00365521.2020.1748224.
    >> Share

  161. SHRESTHA S, Olen O, Eriksson C, Everhov AH, et al
    The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
    Scand J Gastroenterol. 2020;55:430-435.
    >> Share

  162. ZHAO L, Tang Y, Lei N, Zhou D, et al
    Clinical features and monocyte/macrophage subsets characterization in granulomatous vs non-granulomatous Crohn's disease.
    Scand J Gastroenterol. 2020;55:442-448.
    >> Share

  163. KRISTENSEN VA, Cvancarova M, Hoivik ML, Moum B, et al
    Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study.
    Scand J Gastroenterol. 2020;55:436-441.
    >> Share

  164. FREITAS M, Arieira C, Carvalho PB, Rosa B, et al
    Simplify to improve in capsule endoscopy - TOP 100 is a swift and reliable evaluation tool for the small bowel inflammatory activity in Crohn's disease.
    Scand J Gastroenterol. 2020;55:408-413.
    >> Share

    February 2020
  165. DAVIES M, Dodd S, Coultate M, Ross A, et al
    From Paris to Montreal: disease regression is common during long term follow-up of paediatric Crohn's disease.
    Scand J Gastroenterol. 2020;55:148-153.
    >> Share

    January 2020
  166. MOLANDER P, Kemppainen H, Ilus T, Sipponen T, et al
    Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases.
    Scand J Gastroenterol. 2020;55:34-40.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016